Ensign Peak Advisors, Inc Bei Gene, Ltd. Transaction History

Ensign Peak Advisors, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $58,550 - $73,402	200 Added 6.45%	3,300 $1.13 Million
Q1 2021 May 12, 2021	BUY	$260.64 - $382.12 $599,472 - $878,876	2,300 Added 287.5%	3,100 $1.08 Million
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $188,113 - $269,118	-850 Reduced 51.52%	800 $207,000
Q3 2020 Nov 12, 2020	SELL	$189.18 - $286.44 $37,836 - $57,288	-200 Reduced 10.81%	1,650 $473,000
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $214,193 - $385,429	1,850 New	1,850 $307,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.